8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2020 / Pilot double-blind randomized placebo-controlled trial
Patients with mild Alzheimer's disease were randomized to receive three 350 mg erinacine A-enriched Hericium erinaceus mycelia (EAHE) capsules per day (5 mg/g erinacine A) or placebo for 49 weeks following a 3-week screening period. After 49 weeks, the EAHE group showed significant improvement in MMSE score, a significant difference in IADL score compared to placebo, and a significant decrease in CASI score was noted only in the placebo group. The EAHE group also achieved significantly better contrast sensitivity and showed differences in biomarkers and neuroimaging ADC values compared to placebo. Four subjects dropped out due to abdominal discomfort, nausea, and skin rash, with no other adverse events reported.
Li IC, Chang HH, Lin CH, et al. Front Aging Neurosci, 2020. PMID 32581767
2020 / Randomized, double-blinded, placebo-controlled clinical trial
A 6-month trial examined the effects of vitamin D3, enhanced vitamin D2 in a mushroom matrix, standard mushroom, and placebo in 436 healthy adults aged ≥60 years. Total 25-OH-D and 25-OH-D3 levels were maintained in the vitamin D3 arm but decreased significantly (p < 0.05) in the other three arms. There were no significant effects of treatment on any measures of cognitive function or mood over 24 weeks.
Zajac IT, Barnes M, Cavuoto P, et al. Nutrients, 2020. PMID 33339304
2019 / Randomized, double-blind, placebo-controlled parallel-group comparative study
A randomized, double-blind, placebo-controlled parallel-group comparative study evaluated the effect of Hericium erinaceus fruiting body supplements taken for 12 weeks on cognitive functions. Cognitive performance was assessed using the Mini Mental State Examination (MMSE), Benton visual retention test, and Standard verbal paired-associate learning test (S-PA). MMSE alone showed that oral intake of H. erinaceus significantly improved cognitive functions and prevented deterioration.
Saitsu Y, Nishide A, Kikushima K, et al. Biomed Res, 2019. PMID 31413233
2016 / Retrospective analysis of a dietary intervention study
Researchers retrospectively analyzed data from 37 adults with metabolic syndrome who consumed 100 g of white button mushrooms daily for 16 weeks, followed by a one-month mushroom-free period. At 16 weeks, participants showed a doubling of serum ergothioneine, increases in ORAC and adiponectin, and significant decreases in carboxymethyllysine (CML) and methylglyoxal (MG). No changes were observed in 8-isoprostane, leptin, or measures of insulin resistance or glucose metabolism. The authors noted that well-controlled studies are needed to confirm these findings.
Calvo MS, Mehrotra A, Beelman RB, et al. Plant Foods Hum Nutr, 2016. PMID 27193019
2016 / Double-blind, placebo-controlled human clinical trial
A double-blind, placebo-controlled clinical trial evaluated the immune-modulating effects of Pleurotus cornucopiae (Oyster mushroom, Tamogitake) extract ingested for 8 weeks. Intake of the extract significantly elevated serum IFN-γ (P = 0.013) and elevated IL-12, whereas serum levels of IL-10, IL-13, and other cytokines showed minimal changes. Natural killer cell activity tended to increase, but the change was not statistically significant.
Tanaka A, Nishimura M, Sato Y, et al. J Tradit Complement Med, 2016. PMID 27774430
2015 / Randomized controlled trial
Fifty-two healthy adults consumed 5 g or 10 g of dried shiitake mushrooms daily for 4 weeks in a parallel-group trial. Mushroom intake increased ex vivo proliferation of γδ-T cells by 60% and natural killer T cells twofold (both p < 0.0001), along with greater activation receptor expression. Salivary secretory immunoglobulin A increased and serum C-reactive protein decreased, accompanied by distinct shifts in cytokine secretion profiles.
Dai X, Stanilka JM, Rowe CA, et al. J Am Coll Nutr, 2015. PMID 25866155
2015 / Phase I trial
Thirty-six patients with rising prostate-specific antigen levels received escalating doses of white button mushroom powder in a phase I trial. No dose-limiting toxicities occurred, and the overall prostate-specific antigen response rate was 11%. Complete responses occurred in two patients receiving 8 and 14 g/d, with reductions to undetectable levels lasting 49 and 30 months.
Twardowski P, Kanaya N, Frankel P, et al. Cancer, 2015. PMID 25989179
2012 / Randomized controlled trial
In a randomized trial, 24 healthy adults consumed their normal diet alone or with 100 g daily of blanched white button mushrooms for one week. The mushroom group showed a significant increase in mean salivary immunoglobulin A secretion rate of 53% at week one and 56% at week two relative to week zero (P < 0.0005), returning to baseline by week three. No significant changes occurred in the control group.
Jeong SC, Koyyalamudi SR, Pang G Nutrition, 2012. PMID 22113068
2012 / Randomized controlled trial
Thirty-eight healthy adults were randomized to 4 groups consuming standard meals for 6 weeks: untreated mushrooms (control, 0.85 μg/d ergocalciferol), UV-treated mushrooms at 8.8 μg/d (M1) or 17.1 μg/d (M2), or purified ergocalciferol supplement plus untreated mushrooms (28.2 μg/d, S). At week 6, serum 25(OH)D2 increased by 1.2 ± 5.2 in C, 13.8 ± 7.3 in M1, 12.7 ± 3.7 in M2, and 32.8 ± 3.3 nmol/L in S. Concurrently, 25(OH)D3 decreased by -3.9 ± 16.3 in C, -10.4 ± 6.4 in M1, -20.6 ± 14.6 in M2, and -29.5 ± 15.9 nmol/L in S. Overall, ergocalciferol was absorbed and metabolized to 25(OH)D2 but did not affect overall vitamin D status because 25(OH)D3 decreased proportionally.
Stephensen CB, Zerofsky M, Burnett DJ, et al. J Nutr, 2012. PMID 22623385
2011 / 5-week, single-blinded, randomized, placebo-controlled trial
In a 5-week trial during winter, 26 young adults with serum 25OHD <= 50 nmol/l were randomized to receive 28,000 IU (700 ug) vitamin D2 via an experimental mushroom soup, 28,000 IU vitamin D2 via a supplement, or placebo. After 2 weeks, serum 25OHD was significantly higher in the mushroom group than in the placebo group (P=0.001). Serum 25OHD concentrations rose significantly and similarly in the mushroom and supplement groups over the study period by 3.9 nmol/l per week (95% CI: 2.9, 4.8) and 4.7 nmol/l per week (95% CI: 3.8, 5.7), respectively.
Urbain P, Singler F, Ihorst G, et al. Eur J Clin Nutr, 2011. PMID 21540874
2010 / Open-label study
In an open-label study, 51 patients with biochemical failure following radical prostatectomy for non-metastasized prostate cancer took either Senseiro (Agaricus blazei Murill extract, n=32) or Rokkaku Reishi (Ganoderma lucidum, n=15) for 6 months. Forty-seven patients completed the protocol and were assessed. No partial response (a 50% or greater decrease in serum PSA) was observed in any patient. Alteration of PSA doubling time did not correlate with serum testosterone levels, and no serious adverse effects were observed.
Yoshimura K, Kamoto T, Ogawa O, et al. Int J Urol, 2010. PMID 20412340
2009 / Double-blind, parallel-group, placebo-controlled randomized trial
Thirty Japanese men and women aged 50 to 80 with mild cognitive impairment were randomized to take either Yamabushitake (four 250 mg tablets containing 96% dry powder three times daily) or placebo for 16 weeks, followed by 4 weeks of observation. At weeks 8, 12, and 16, the Yamabushitake group showed significantly increased cognitive function scale scores compared with placebo, with scores increasing with duration of intake. However, scores decreased significantly by 4 weeks after terminating intake. Laboratory tests showed no adverse effects.
Mori K, Inatomi S, Ouchi K, et al. Phytother Res, 2009. PMID 18844328
2002 / Open-label clinical trial
Sixty-two men with histologically proven prostate cancer and elevated PSA received shiitake mushroom mycelium extract capsules three times daily for 6 months. Among 61 assessable patients, zero achieved a complete or partial PSA response, 23 developed disease progression, and 38 maintained stable PSA levels. When pre-study PSA trajectories were examined, only 4 of 61 patients (7%) demonstrated stabilized disease while taking the supplement.
deVere White RW, Hackman RM, Soares SE, et al. Urology, 2002. PMID 12385925